Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | METAP2 | P50579 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577937 | 0.81 | METAP2 (0.39) | NOS1METAP2ADORA2ALRRK2TRPA1 | |
| SCHEMBL11577531 | 0.79 | NOS1 (0.53) | NOS1METAP2CSNK2A1DYRK1AIDO1 | |
| SCHEMBL19204860 | 0.76 | NOS1 (0.46) | NOS1METAP2DYRK1AIDO1TDO2 | |
| SCHEMBL3601695 | 0.76 | NOS1 (0.50) | NOS1METAP2CSNK2A1DYRK1AIDO1 | |
| SCHEMBL3515094 | 0.76 | MAPT (0.46) | NOS1METAP2ADORA2ALRRK2TRPA1 | |
| SCHEMBL20112865 | 0.76 | NOS1 (0.46) | NOS1METAP2IDO1ADORA2ALRRK2 | |
| SCHEMBL18107535 | 0.76 | FGFR1 (0.44) | NOS1METAP2IDO1ADORA2ALRRK2 | |
| SCHEMBL758690 | 0.76 | NOS1 (0.46) | NOS1METAP2CSNK2A1DYRK1AIDO1 | |
| SCHEMBL19204828 | 0.76 | LRRK2 (0.40) | NOS1METAP2IDO1ADORA2ALRRK2 | |
| SCHEMBL31472072 | 0.76 | NOS1 (0.46) | NOS1METAP2CSNK2A1DYRK1AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025235733-A1 | BIS-BICYCLOHETEROARYL MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | NOS1 387/4885METAP2 4393/4885CSNK2A1 85/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | NOS1 4376/4885METAP2 3441/4885CSNK2A1 1805/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | NOS1 4186/4885METAP2 4459/4885CSNK2A1 77/4885 |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | NOS1 3625/4885METAP2 1741/4885CSNK2A1 781/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | NOS1 1628/4885METAP2 2059/4885CSNK2A1 3515/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | NOS1 1666/4885METAP2 3277/4885CSNK2A1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.